DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Lupus is a condition often shrouded in mystery. Presenting with a huge range of symptoms, it’s tricky to diagnose, tough to ...

The spleen is essential for filtering blood, supporting immune function, and managing red blood cells. However, in cases of immune disorders, it can become overactive, leading to enlargement.

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...